Emmaus Life Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

LOSS PER SHARE

LOSS PER SHARE

3 Months Ended

Dec. 31, 2016

LOSS PER SHARE

In accordance with ASC 260-10 (formerly SFAS 128, “Computation of Earnings Per Share”), basic net income (loss) per share is computed by dividing the net income (loss) to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of common and dilutive common equivalent shares outstanding during the period. For the three-month periods ended December 31, 2016 and 2015, the Company has excluded all common equivalent shares from the calculation of diluted net loss per share as such securities are anti-dilutive.

A summary of the net income (loss) and shares used to compute net income (loss) per share for the three-month periods ended December 31, 2016 and 2015 is as follows:

	Three months ended December 31,
	2016			2015
Net Loss for computation of basic and diluted net loss per share:
Net loss	$	(1,463,800	)	$	(3,451,300	)
Basic and Diluted net loss per share:
Basic net loss per share	$	(0.70	)	$	(6.74	)

Basic and Diluted weighted average shares outstanding		2,101,061			512,087

Anti-dilutive common equivalent shares not included in the computation of dilutive net loss per share:
Convertible debt		-			315,982
Warrants		7,155			34,227
Options		325,103			71,150